HENDERSON, NV -- (Marketwired) -- 04/07/15 -- United Health Products Inc. (OTCQB: UEEC) has received the final laboratory test results and pathology reports for recent porcine testing. The laboratory tests were performed at Mount Sterling Laboratories, and the autopsy and pathology performed at the Utah Veterinary Diagnostic Laboratory, Utah State University. The test protocol was designed to determine the length of time required to achieve hemostasis on a lateral femoral artery cut in pigs. Hemostasis is a process which causes bleeding to stop. As part of the protocol, the HemoStyp® gauze was placed on the wound site and upon achieving hemostasis, the product was left on the wound site without any sutures, bands, clamps, etc. The wound site was then closed with another strip of HemoStyp® that was placed just under the skin. Complete hemostasis was achieved within 25 minutes on the incision of the femoral artery. Upon completion of the test, with the HemoStyp® gauze remaining in the cavity, the pigs were placed in an enclosure and allowed to recover. Ten hours after the procedures, two of the three pigs were up and walking, the third pig did not naturally recover. The two pigs were penned and monitored for three weeks eating and gaining weight as they resumed an active life. After three weeks, the pigs were euthanized and autopsied.
The autopsy results determined that there was no trace of HemoStyp® product or residue of the product remained in the body or any of the organs. Douglas Beplate, CEO said, "The results are remarkable in that they not only show that HemoStyp® is effective at rapid hemostasis in a wound site, but prove it is totally absorbable into the body." He added, "In my opinion HemoStyp® promotes vascular genesis and healing."
The tests reports were furnished to the U.S. Military will be posted for viewing on the United Health Products Inc. website.
About United Health Products Inc.
United Health Products Inc. (UEEC) develops, manufactures, and markets patented hemostatic gauze, for the healthcare and wound care sectors. The product, HemoStyp®, is derived from regenerated oxidized cellulose, which is all natural, and designed to absorb exudate/drainage from superficial wounds and helps control bleeding. UEEC is focused on identifying new markets and applications for its product as well as ramping up sales in its current markets. For more on United Health Products Inc. visit: www.unitedhealthproductsinc.com
Safe Harbor Statement
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This news release may contain forward-looking information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements that include the words "believes," "expects," "anticipates" or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to differ materially from those expressed or implied by such forward-looking statements.
United Health Products Inc.